Endothelial Hypoxia-Inducible Factor-1α Promotes Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a
Overview
Authors
Affiliations
Chemokines mediate monocyte adhesion to dysfunctional endothelial cells (ECs) and promote arterial inflammation during atherosclerosis. Hypoxia-inducible factor (HIF)-1α is expressed in various cell types of atherosclerotic lesions and is associated with lesional inflammation. However, the impact of endothelial HIF-1α in atherosclerosis is unclear. HIF-1α was detectable in the nucleus of ECs covering murine and human atherosclerotic lesions. To study the role of endothelial HIF-1α in atherosclerosis, deletion of the Hif1a gene was induced in ECs from apolipoprotein E knockout mice (EC-Hif1a(-/-)) by Tamoxifen injection. The formation of atherosclerotic lesions, the lesional macrophage accumulation, and the expression of CXCL1 in ECs were reduced after partial carotid ligation in EC-Hif1a(-/-) compared with control mice. Moreover, the lesion area and the lesional macrophage accumulation were decreased in the aortas of EC-Hif1a(-/-) mice compared with control mice during diet-induced atherosclerosis. In vitro, mildly oxidized low-density lipoprotein or lysophosphatidic acid 20:4 increased endothelial CXCL1 expression and monocyte adhesion by inducing HIF-1α expression. Moreover, endothelial Hif1a deficiency resulted in downregulation of miR-19a in atherosclerotic arteries determined by microRNA profiling. In vitro, HIF-1α-induced miR-19a expression mediated the upregulation of CXCL1 in mildly oxidized low-density lipoprotein-stimulated ECs. These results indicate that hyperlipidemia upregulates HIF-1α expression in ECs by mildly oxidized low-density lipoprotein-derived unsaturated lysophosphatidic acid. Endothelial HIF-1α promoted atherosclerosis by triggering miR-19a-mediated CXCL1 expression and monocyte adhesion, indicating that inhibition of the endothelial HIF-1α/miR-19a pathway may be a therapeutic option against atherosclerosis.
Hou Y, Zhao Y, Shi Z, Pan Y, Shi K, Zhao C Int J Med Sci. 2025; 22(4):873-886.
PMID: 39991758 PMC: 11843136. DOI: 10.7150/ijms.100572.
Stratakis N, Anguita-Ruiz A, Fabbri L, Maitre L, Gonzalez J, Andrusaityte S Nat Commun. 2025; 16(1):654.
PMID: 39809770 PMC: 11732992. DOI: 10.1038/s41467-025-56013-7.
Hypoxia and aging: molecular mechanisms, diseases, and therapeutic targets.
Nisar A, Khan S, Li W, Hu L, Samarawickrama P, Gold N MedComm (2020). 2024; 5(11):e786.
PMID: 39415849 PMC: 11480526. DOI: 10.1002/mco2.786.
Pirri D, Tian S, Tardajos-Ayllon B, Irving S, Donati F, Allen S Circ Res. 2024; 135(8):822-837.
PMID: 39234692 PMC: 11424061. DOI: 10.1161/CIRCRESAHA.123.324054.
MicroRNA-19a-3p inhibits endothelial dysfunction in atherosclerosis by targeting JCAD.
Luo J, Wang L, Cui C, Chen H, Zeng W, Li X BMC Cardiovasc Disord. 2024; 24(1):394.
PMID: 39080547 PMC: 11287888. DOI: 10.1186/s12872-024-04063-y.